Safety

Casodex (bicalutamide) tablet

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

February 2015

Summary View

ADVERSE REACTIONS

Post-Marketing Experience
  • Respiratory disorders: Interstitial lung disease (some fatal) including interstitial pneumonitis and pulmonary fibrosis, most often at doses greater than 50 mg
  • Skin and subcutaneous tissue disorders: Photosensitivity 

 

September 2010

Summary View

WARNINGS AND PRECAUTIONS

Hepatitis
  • Cases of death or hospitalization due to severe liver injury (hepatic failure) have been reported postmarketing in association with the use of Casodex.

 

Page Last Updated: 03/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.